InfuSystem Holdings Inc

InfuSystem Holdings Inc(INFU)股票分析

$12.180

+0.040 (+0.33%)收盘时

Loading chart…
High
12.470
Open
12.290
VWAP
12.21
Vol
72.45K
Mkt Cap
145.87M
Low
11.995
Amount
884.94K
EV/EBITDA, TTM
8.82

InfuSystem Holdings, Inc. is a national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. Its segments include Patient Services and Device Solutions. Its core service within its Patient Services segment is its Oncology Business. Patient Services supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its Device Solutions segment’s core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment, sell treatment-related consumables, and provide biomedical recertification, maintenance and repair services for oncology practices and other healthcare site settings, including, home care and home infusion providers and others.

AI analysis of InfuSystem Holdings Inc (INFU)

buy

InfuSystem Holdings Inc is a good buy right now, primarily due to its recent earnings report showing a profit of $3.23 million, translating to $0.15 per share, which is a significant increase from $2.60 million and $0.12 per share last year. Additionally, the company's forward P/E ratio of 22.73 suggests that it is reasonably valued for its growth potential, especially with a projected revenue growth of 6% to 8% for 2026. However, a key risk is the 16% decline in Device Solutions revenue, which could impact overall performance if not addressed.

估值指标

The current forward P/E ratio for InfuSystem Holdings Inc (INFU) is 22.73, compared to its 5-year average forward P/E of 69.53.

Forward P/E

Fair
5Y Average P/E
69.53
Current P/E
22.73
高估
140.21
低估
-1.14

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
8.86
Current EV/EBITDA
8.82
高估
11.16
低估
6.57

Forward P/S

Fair
5Y Average P/S
1.45
Current P/S
1.60
高估
1.94
低估
0.97

Alphio AI Price Scenarios for INFU

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%INFU

$7.68

情景价格

B

Base

Base · 50%INFU

$6.54

情景价格

B

Bear

Bear · 25%INFU

$6.33

情景价格

事件时间线

2026-08-04 (ET)

07:00:00

Sees 2026 Adjusted EBITDA Margin in Mid to Low 20%'s

07:00:00

Company Reports Q2 Revenue of $36.9M

2026-05-18 (ET)

16:40:00

InfuSystem Approves $20M Stock Repurchase Program

2026-05-07 (ET)

07:30:00

Q1 Revenue at $33.7M, Below Consensus

2026-03-02 (ET)

09:40:00

InfuSystem Trading Resumes

资讯

INFU FAQ — answered by Alphio AI

InfuSystem Holdings, Inc. is a national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. Its segments include Patient Services and Device Solutions. Its core service within its Patient Services segment is its Oncology Business. Patient Services supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its Device Solutions segment’s core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment, sell treatment-related consumables, and provide biomedical recertification, maintenance and repair services for oncology practices and other healthcare site settings, including, home care and home infusion providers and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

InfuSystem Holdings Inc is a good buy right now, primarily due to its recent earnings report showing a profit of $3.23 million, translating to $0.15 per share, which is a significant increase from $2.60 million and $0.12 per share last year. Additionally, the company's forward P/E ratio of 22.73 suggests that it is reasonably valued for its growth potential, especially with a projected revenue growth of 6% to 8% for 2026. However, a key risk is the 16% decline in Device Solutions revenue, which could impact overall performance if not addressed.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始